Durvalumab Clinical Trials

119 actively recruiting trials across 43 locations

Also known as: 1428935-60-7, DURVALUMAB, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), 1428935-60-7, Durvalumab (DURVALUMAB, Imfinzi), Immunoglobulin G1, Anti-B7-H1 mAb (MEDI4736, heavy/kappa-chain disulfide, dimer, Consolidation treatment, Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, IMFINZI, IMFINZI®, Imfimzi, Imfinzi, Imjudo, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, MEDI4736 & IMFINZI®, MEDI4736, IMFINZI, anti-Programmed cell death protein 1 (PD-L1) inhibitor, durvalumab Injection [Imfinzi]

Filter by location:

Other49 trials

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase 2

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Phase 1

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

N/A

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Phase 1/2

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

Phase 2

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Phase 2

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Phase 1/2

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Phase 1/2

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Phase 2

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Phase 3

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Phase 2

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Phase 2

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Phase 2

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Phase 2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Phase 4

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Phase 2

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Phase 2

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Phase 2

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Phase 2

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Phase 1/2

Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy

Phase 2

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Phase 2

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Phase 2

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Phase 2

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

Phase 2

Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Phase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Phase 2

Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

Phase 2/3

Renal Adjuvant MultiPle Arm Randomised Trial

Phase 3

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Phase 2

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

Phase 2

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Phase 2

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Phase 3

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Phase 2

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

Phase 2

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Phase 2

Birmingham, Alabama6 trials

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

University of Alabama at Birmingham

Phase 2

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Research Site

Phase 3

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Research Site

Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

University of Alabama at Birmingham

Phase 1/2

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Duarte, California6 trials

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 2

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

City of Hope

Phase 1

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Baltimore, Maryland4 trials

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Mercy Medical Center - Medline Healthcare Services LLC

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Maryland Proton Treatment Center

Phase 1

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Johns Hopkins SKCCC

Phase 1/2

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

SKCCC Johns Hopkins Medical Institution

Phase 1

Irvine, California3 trials

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

City of Hope Orange County Lennar Foundation Cancer Center

Phase 1

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1

Stanford, California3 trials

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

GSK Investigational Site

Phase 1

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Stanford University

Phase 2

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3

Chicago, Illinois3 trials

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

University of Illinois Medical Center

Phase 2

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

University of Chicago Medicine

Phase 2

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

The University of Chicago Medical Center

Phase 2

Boston, Massachusetts3 trials

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Massachusetts General Hospital

Phase 2

TRUDI: TDXD+Durva in HER2+/Low IBC

Brigham and Women's Hospital

Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2

Houston, Texas3 trials

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

MD Anderson Cancer Center

Phase 1/2

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M D Anderson Cancer Center

Phase 2

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

M D Anderson Cancer Center

Phase 2

Daphne, Alabama2 trials

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Research Site

Phase 3

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Southern Cancer Center

Phase 2

Jonesboro, Arkansas2 trials

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Saint Bernards Medical Center

Phase 3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Phase 3

Orange, California2 trials

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Chao Family Comprehensive Cancer Center, University

Phase 1

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Tampa, Florida2 trials

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Moffitt Cancer Center

Phase 2

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Moffitt Cancer Center

Phase 1

Huntsville, Alabama1 trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Chandler, Arizona1 trial

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Research Site

Phase 3

Kingman, Arizona1 trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Kingman Regional Medical Center

Phase 2/3

Scottsdale, Arizona1 trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Site

Phase 3

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Beverly Hills, California1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Beverly Hills Cancer Center

Phase 2

Buena Park, California1 trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Keck Medicine of USC Buena Park

Phase 2

Fresno, California1 trial

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Los Angeles, California1 trial

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Cedars-Sinai Medical Center

Phase 1

Palo Alto, California1 trial

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stanford Cancer Institute Palo Alto

Phase 2

San Diego, California1 trial

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

University of California, San Diego

Phase 1

San Francisco, California1 trial

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

University of California, San Francisco

Phase 2

Santa Monica, California1 trial

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Aurora, Colorado1 trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

University of Colorado Anschutz Medical Campus ( Site 1110)

Phase 1/2

Denver, Colorado1 trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Sarah Cannon Research Institute at HealthONE

Phase 1/2

Farmington, Connecticut1 trial

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Connecticut Health Center

Phase 2

Newark, Delaware1 trial

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Helen F Graham Cancer Center

Phase 2

Washington D.C., District of Columbia1 trial

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Georgetown Lombardi Comprehensive Cancer Center

Phase 2

Jacksonville, Florida1 trial

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic in Florida

Phase 1

Atlanta, Georgia1 trial

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Grady Health System

Phase 2

Westwood, Kansas1 trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

University of Kansas Cancer Center

Phase 1/2

Bethesda, Maryland1 trial

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute Developmental Therapeutics Clinic

Phase 2

Ann Arbor, Michigan1 trial

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

University of Michigan Comprehensive Cancer Center

Phase 2

Detroit, Michigan1 trial

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

Henry Ford Cancer- Detroit

Phase 2

Rochester, Minnesota1 trial

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic in Rochester

Phase 1/2

Winston-Salem, North Carolina1 trial

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

UPMC Hillman Cancer Center

Phase 2

San Antonio, Texas1 trial

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

UT Health San Antonio

Phase 2

Salt Lake City, Utah1 trial

Tumor Treating Fields for Locally Advanced NSCLC

Huntsman Cancer Institute

Phase 1

Charlottesville, Virginia1 trial

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

University of Virginia

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.